Safety and efficacy of MIM D3 ophthalmic solutions in a randomized placebo controlled Phase 2 clinical trial in patients with dry eye

Código QR

Safety and efficacy of MIM D3 ophthalmic solutions in a randomized placebo controlled Phase 2 clinical trial in patients with dry eye

Karen Meerovitch,1 Gail Torkildsen,2 John Lonsdale,3 Heidi Goldfarb,4 Teresa Lama,1 Garth Cumberlidge,1 George W Ousler III5 1Mimetogen Pharmaceuticals Inc, Montreal, QC, Canada; 2Andover Eye Associates, Andover, MA, USA; 3Central Maine Eye Care, Lewiston, ME, USA; 4SDC, Tempe, AZ, USA; 5Ora Inc, An...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Meerovitch K, Torkildsen G, Lonsdale J, Goldfarb H, Lama T, Cumberlidge G, Ousler GW III
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/0c3f798104ab4f9a87e7bc3bca99479b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model
por: Sosne G, et al.
Publicado: (2015)

The IMPACT study: a prospective evaluation of the effects of cyclosporine ophthalmic emulsion 0.05% on ocular surface staining and visual performance in patients with dry eye
por: Stonecipher KG, et al.
Publicado: (2016)

An evaluation of Retaine™ ophthalmic emulsion in the management of tear film stability and ocular surface staining in patients diagnosed with dry eye
por: Ousler III G, et al.
Publicado: (2015)

Ocular iontophoresis of EGP-437 (dexamethasone phosphate) in dry eye patients: results of a randomized clinical trial
por: Patane MA, et al.
Publicado: (2011)

A phase 2 randomized, double-masked, placebo-controlled study of novel nonsystemic kinase inhibitor TOP1630 for the treatment of dry eye disease
por: Taylor M, et al.
Publicado: (2019)

Automated grading system for evaluation of ocular redness associated with dry eye
por: Rodriguez JD, et al.
Publicado: (2013)

Investigation of extended blinks and interblink intervals in subjects with and without dry eye
por: Rodriguez JD, et al.
Publicado: (2013)

Clinical utility of 3% diquafosol ophthalmic solution in the treatment of dry eyes
por: Koh S
Publicado: (2015)

Practical guidance for the use of cyclosporine ophthalmic solutions in the management of dry eye disease
por: de Oliveira RC, et al.
Publicado: (2019)

Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye
por: White DE, et al.
Publicado: (2019)

Safety of cetirizine ophthalmic solution 0.24% for the treatment of allergic conjunctivitis in adult and pediatric subjects
por: Malhotra RP, et al.
Publicado: (2019)

Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy
por: Godin MR, et al.
Publicado: (2017)

Review of hydroxypropyl cellulose ophthalmic inserts for treatment of dry eye
por: Nguyen T, et al.
Publicado: (2011)

Blink patterns and lid-contact times in dry-eye and normal subjects
por: Ousler GW 3rd, et al.
Publicado: (2014)

The interblink interval in normal and dry eye subjects
por: Johnston PR, et al.
Publicado: (2013)

Effects of 3% diquafosol sodium ophthalmic solution on higher-order aberrations in patients diagnosed with dry eye after cataract surgery
por: Inoue Y, et al.
Publicado: (2016)

Rebamipide ophthalmic suspension for the treatment of dry eye syndrome: a critical appraisal
por: Kashima T, et al.
Publicado: (2014)

Preclinical Efficacy Comparison of Cyclosporine Ophthalmic Solution 0.09% vs Cyclosporine Ophthalmic Emulsion 0.05% vs Ciclosporin Ophthalmic Emulsion 0.1% in a NOD Mouse Model of Dry Eye Disease
por: Burade V, et al.
Publicado: (2020)

Review of moxifloxacin hydrochloride ophthalmic solution in the treatment of bacterial eye infections
por: Darlene Miller
Publicado: (2008)

Safety and efficacy of lifitegrast 5% ophthalmic solution in contact lens discomfort
por: Gonzalez AL
Publicado: (2018)

Dry Eye Treatment with Topical Cyclosporine 0.1% in Chondroitin Sulfate Ophthalmic Emulsion
por: Matossian C, et al.
Publicado: (2021)

Exacerbation of signs and symptoms of allergic conjunctivitis by a controlled adverse environment challenge in subjects with a history of dry eye and ocular allergy
por: Gomes PJ, et al.
Publicado: (2013)

Safety and comfort evaluation of a new formulation of Visine® lubricant eye drops containing HydroBlend™ and GentlePur™
por: Torkildsen G, et al.
Publicado: (2016)

Patient and physician perspectives on the use of cyclosporine ophthalmic emulsion 0.05% for the management of chronic dry eye
por: Deveney T, et al.
Publicado: (2018)

A randomized, double-blind, placebo-controlled study of oral antioxidant supplement therapy in patients with dry eye syndrome
por: Huang JY, et al.
Publicado: (2016)

Tear volume estimation using a modified Schirmer test: a randomized, multicenter, double-blind trial comparing 3% diquafosol ophthalmic solution and artificial tears in dry eye patients
por: Miyake H, et al.
Publicado: (2016)

The Impact of the COVID-19 Pandemic on Ophthalmic Care at an Eye-Specific Emergency Department in an Outbreak Hotspot
por: Moon JY, et al.
Publicado: (2020)

RGN-259 (thymosin β4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model
por: Chae Eun Kim, et al.
Publicado: (2018)

Randomized, Double-Masked, Placebo-Controlled Dose Escalation Study of TAK-639 Topical Ophthalmic Solution in Subjects with Ocular Hypertension or Primary Open-Angle Glaucoma
por: Martin P, et al.
Publicado: (2020)

Phase III trials examining the efficacy of cetirizine ophthalmic solution 0.24% compared to vehicle for the treatment of allergic conjunctivitis in the conjunctival allergen challenge model
por: Meier EJ, et al.
Publicado: (2018)

Safety and efficacy of amniotic cytokine extract in the treatment of dry eye disease
por: Yeu E, et al.
Publicado: (2019)

Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy
por: J Charles Henry, et al.
Publicado: (2008)

A Comparison of Efficacy and Safety of Two Lipid-Based Lubricant Eye Drops for the Management of Evaporative Dry Eye Disease
por: Jerkins G, et al.
Publicado: (2020)

Real-World Experience with Lifitegrast Ophthalmic Solution (Xiidra®) in the US and Canada: Retrospective Study of Patient Characteristics, Treatment Patterns, and Clinical Effectiveness in 600 Patients with Dry Eye Disease
por: Hovanesian JA, et al.
Publicado: (2021)

Ocular pharmacokinetics of bimatoprost formulated in DuraSite compared to bimatoprost 0.03% ophthalmic solution in pigmented rabbit eyes
por: Shafiee A, et al.
Publicado: (2013)

Prolonged increase in tear meniscus height by 3% diquafosol ophthalmic solution in eyes with contact lenses
por: Nagahara Y, et al.
Publicado: (2015)

Influence of container structures and content solutions on dispensing time of ophthalmic solutions
por: Keiji Yoshikawa, et al.
Publicado: (2010)

Efficacy of vitrectomy and epiretinal membrane peeling in eyes with dry age-related macular degeneration
por: Mason III JO, et al.
Publicado: (2015)

Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%
por: Jack V Greiner, et al.
Publicado: (2011)

Clinical utility of voriconazole eye drops in ophthalmic fungal keratitis
por: Daoud Al-Badriyeh, et al.
Publicado: (2010)